Extend Biosciences is focused on developing innovative drug delivery solutions that enhance the pharmacokinetic properties of peptides and proteins through its proprietary D-VITylation® technology. This platform addresses the challenge of short half-lives that often hinder the therapeutic potential of peptides, which are typically eliminated from circulation quickly. By covalently attaching a derivative of vitamin D to peptides, the D-VITylation® technology significantly improves their circulating half-life and bioavailability. This advancement allows for less frequent dosing, potentially transforming the administration of peptide-based therapies into a more patient-friendly experience.

The company is currently advancing multiple compounds utilizing this technology, including EXT608 for hypoparathyroidism and EXT418 for diabetes-induced peripheral neuropathy and cachexia. EXT608 aims to provide a long-acting solution for patients with low parathyroid hormone levels, while EXT418 seeks to leverage the properties of ghrelin to address painful neuropathy and cachexia, both of which are associated with significant morbidity. By enhancing the therapeutic efficacy and reducing the frequency of administration, Extend Biosciences' D-VITylation® technology has the potential to improve patient outcomes and quality of life in chronic disease management.

United States

Extend Biosciences is a biotechnology company that focuses on enabling technologies for the efficient and sustained delivery of peptides and proteins.

Extend Biosciences

Company Details